The primary purpose of this Hormone Replacement Therapy is used to address symptomatic discomfort in postmenopausal women. The formulation is primarily relevant in clinical settings marked by heightened patient distress caused by chronic symptoms. The treatment is commonly applied across three key therapeutic domains: management of vasomotor symptom clusters, support for urogenital atrophy, and supportive management of skeletal health.

The therapeutic focus is on easing the overall symptom burden when patients experience hot flushes, night sweats, vaginal dryness, or localized irritation, as well as addressing the risk of bone loss. The supportive relief provided by this treatment assists with maintaining functional stability and contributes to improved comfort during periods when symptoms are more noticeable.

“The therapeutic focus helps ease the overall symptom burden, supporting general well-being.”

Quick Fact: Symptomatic Relief Domains
Vasomotor	Helps ease the overall burden of hot flushes and night sweats.
Urogenital	Contributes to improved comfort from dryness and irritation.
Skeletal	Supports addressing the risk of bone loss.

Who Can and Cannot Use Angeliq Micro?

Eligibility for Angeliq Micro (Estradiol/Drospirenone) is strictly defined by regulatory documents, limiting its use to the population for which it has been approved and listing specific exclusions.

Populations Explicitly Allowed to Use the Medicine

Angeliq Micro is approved for use exclusively in adult women who are postmenopausal.

---

Absolute Contraindications (Must Not Use)

Use of this medicine is absolutely prohibited in patients with certain conditions, including:

• Active or history of venous or arterial thromboembolic disease (e.g., stroke, heart attack, DVT, PE).
• Known or suspected breast cancer or other estrogen-dependent malignant tumors.
• Severe hepatic disease or severe renal impairment.
• Undiagnosed abnormal genital bleeding.
• Adrenal insufficiency or known thrombophilic disorders.

---

Age and Physiological Restrictions

The medicine is contraindicated in pregnancy and not indicated for use during lactation. It is not indicated for the pediatric population (children and adolescents), as safety and effectiveness have not been established in this age group. Patients with mild to moderate hepatic or renal impairment may require close supervision during use.

Interactions with Other Medicines and Products

The interaction profile of Angeliq Micro is characterized by two main areas of concern based on the regulatory documents for its components: metabolic interference via the CYP450 enzyme system and the risk of hyperkalemia due to the drospirenone component.

---

Interacting Medicines and Substances

Interaction Type	Interacting Categories/Substances	Constraint/Requirement
Metabolic	CYP3A4 Inducers (e.g., St. John's Wort, certain antiepileptics)	May decrease plasma concentrations of the drug's components, potentially reducing efficacy.
Metabolic	CYP3A4 Inhibitors (e.g., strong inhibitors like ketoconazole)	May increase plasma concentrations; monitoring is recommended, particularly for high-risk patients.
Potassium Risk	Potassium-sparing diuretics, ACE inhibitors, Angiotensin-II receptor antagonists, NSAIDs (long-term use), Heparin, Potassium supplements	May increase serum potassium levels (hyperkalemia). Monitoring of serum potassium is necessary, especially during the first month of co-administration in high-risk patients.
Food/Lifestyle	Grapefruit Juice	May increase drug levels and the risk of side effects; avoidance is advised.

---

Procedural and Laboratory Constraints

Estrogen components can influence the results of certain laboratory tests, including those for thyroid function, coagulation, and lipid/glucose metabolism. Women currently taking thyroid hormone replacement therapy may require monitoring of their thyroid status, as the estrogen component can increase thyroid-binding globulin. All high-risk patients taking other potassium-increasing drugs should have their serum potassium concentrations monitored during the initial month of therapy to manage the risk of hyperkalemia.

Angeliq Micro exerts its pharmacological actions through its two components, estradiol and drospirenone, primarily by modulating intracellular receptor signaling pathways.***

Estrogen Receptor Modulation

Estradiol, which is molecularly identical to endogenous estrogen, binds to and activates nuclear estrogen receptors ( ERalpha and ERbeta) in target tissues, including the central nervous system. This activation initiates gene transcription, restoring estrogenic signaling sequences that modulate downstream signaling cascades.

Progesterone Receptor Agonism

Drospirenone, a synthetic progestogen, acts as an agonist at the progesterone receptor (PR). Its binding and activation of PRs introduce an anti-proliferative influence on endometrial cells, modifying gene expression patterns induced by estradiol. This sequential modification of downstream regulatory elements supports localized tissue homeostasis.

Anti-Mineralocorticoid Activity

Drospirenone also acts as an antagonist at the mineralocorticoid receptor (MR). This competitive inhibition of aldosterone binding influences the activity of the renin-angiotensin-aldosterone system (RAAS). Consequently, this antagonism alters epithelial sodium channel activity, resulting in increased renal excretion of sodium and water.

How to use Angeliq Micro: Official Administration Guidelines

Angeliq Micro (drospirenone and estradiol) is a combination hormone therapy that must be taken according to a continuous combined regimen. Adherence to the prescribed administration rules is essential for correct use.

Administration Protocol

Administration Scope	Official Instruction
Route of Administration	Oral (by mouth).
Standard Dosing	One film-coated tablet taken once daily. The lowest effective dose should be used.
Frequency & Timing	One tablet should be taken at approximately the same time every day to maintain a consistent schedule.
Intake Conditions	Swallow the tablet whole with some liquid; it may be taken with or without food. Do not crush, chew, break, or dissolve the tablet.

Continuous Use and Missed Doses

Treatment with Angeliq Micro is continuous, meaning each 28-day pack is followed immediately by the next pack without a break.

• Missed Dose Protocol: If a tablet is forgotten and less than 24 hours have elapsed, the tablet should be taken immediately. If more than 24 hours have elapsed, the missed tablet must be skipped entirely, and the patient should take the next scheduled dose at the regular time. Do not double the dose to compensate for the missed one.

Population and Procedural Constraints

Angeliq Micro is not indicated for use in children and adolescents. The official labeling also restricts its use in specific patient populations, such as those with severe renal or hepatic impairment. Women switching from a cyclic or sequential hormone therapy regimen must complete their current cycle before starting Angeliq Micro.

Research Evidence: Overview of Studies

---

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

Research exploring outcomes related to systemic or functional imbalance, specifically Type 2 Diabetes Mellitus, primarily used short-term and intermediate-term randomized controlled trials (RCTs). These studies examined adults whose blood sugar levels remained above specific targets despite existing background treatments. Research examined outcomes relevant in evidence describing how symptoms are measured, focusing on metrics like glycated hemoglobin (A1C) and fasting plasma glucose (FPG). Studies monitored changes in measurements of A1C and body weight during the study periods. However, follow-up durations were limited in the primary trials. Certainty remains low for some subgroups, and studies describe patterns related to gastrointestinal side effects observed.

---

Evidence for Use in Chronic Weight Management

This agent was studied for chronic weight management in intermediate-term, placebo-controlled RCTs. Research explored outcomes reflecting daily functioning in adults classified as overweight (with related health issues) or obese. These studies monitored specific endpoints, including the percentage change in body weight and the proportion of participants who reached specific weight reduction thresholds. Studies report how weight measurements were observed to change over the study period (e.g., 68 weeks). These studies involved participants who also followed a structured diet and exercise program. Limited information is available for long-term outcomes regarding complex outcomes like cardiovascular events within this specific indication.

---

Evidence for Use in Cardiovascular Risk Reduction (in T2DM)

To evaluate the impact on major heart-related events in people with T2DM, the agent was evaluated in large-scale, long-term Cardiovascular Outcomes Trials (CVOTs). These studies focused on patients who already had established cardiovascular disease or were considered high-risk. Research describes the measured incidence rate of the composite endpoint of cardiovascular death, non-fatal stroke, and non-fatal heart attack over the long-term follow-up period. Results apply only to the populations studied, meaning there is limited information for patients with T2DM who are considered low-risk for heart disease.

---

What is Still Uncertain About the Research

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The key limitations include that follow-up durations were limited in many primary trials, meaning there is limited information for long-term outcomes regarding sustained weight management and blood sugar patterns. Comparative evidence is lacking to definitively contextualize findings. Furthermore, the consistency of findings varies across studies, and data for certain groups, such as those with certain severe medical conditions, remain insufficient. Research is ongoing to address some of these limitations.

Key Studies & References

1. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL Trial)
2. Semaglutide and Cardiovascular Outcomes: Is Weight Loss the Only Factor? (SELECT Trial Analysis)
3. Semaglutide for weight management (STEP 1 Trial and long-term results) - NovoMEDLINK
4. FDA Approves Oral Semaglutide for Cardiovascular (CV) Risk Reduction in Adults with Type 2 Diabetes (Regulatory Update)

Common questions about Angeliq Micro (FAQ)

Q: What is Angeliq Micro and what is it used for?

Angeliq Micro is a combination hormone replacement therapy (HRT) tablet. It contains estradiol, a form of estrogen, and drospirenone, a progestin. It is primarily used to treat the moderate to severe vasomotor symptoms of menopause, such as hot flashes. It may also be used to treat moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Because this product contains a progestin, it is generally recommended for women who still have their uterus (womb).

Q: How does Angeliq Micro work?

The body's natural production of estrogen decreases during menopause, which can lead to uncomfortable symptoms. Angeliq Micro works by replacing the estrogen that is no longer produced, which helps relieve these menopausal symptoms. The estradiol component is the estrogen. The drospirenone component is a progestin, and its main role is to help reduce the risk of endometrial hyperplasia (excessive thickening of the lining of the uterus) and endometrial cancer, which is associated with taking estrogen alone.

Q: How do I take Angeliq Micro?

Angeliq Micro is a continuous combined HRT, meaning the tablets contain both hormones and are taken every day without a break. You should take one tablet daily with some liquid, at approximately the same time each day, regardless of food intake. Once you finish a pack, you should start a new one immediately the next day.

Q: What are the most common side effects of Angeliq Micro?

Common side effects, which may occur in at least 1% of users, can include:

• Gastrointestinal and abdominal pain
• Female genital tract bleeding
• Breast pain and discomfort
• Headache

Q: What is the risk of breast cancer while taking Angeliq Micro?

Combined estrogen-plus-progestin HRT, such as Angeliq Micro, has been associated with an increased risk of invasive breast cancer when used for more than five years. The risk is generally observed to be greater the longer the duration of use. Before starting therapy, a healthcare provider should conduct a thorough physical exam, including a breast exam and a mammogram, and a woman should continue to receive regular breast screening.

Q: Does Angeliq Micro increase the risk of blood clots or stroke?

Yes, taking combined estrogen-plus-progestin HRT is associated with an increased risk of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). These are types of blood clots. The risk is generally increased in women over 60 years of age. A healthcare provider should assess your individual risk factors before you begin treatment.

Q: Who should not take Angeliq Micro (Contraindications)?

Angeliq Micro is contraindicated (should not be taken) if you have:

• Undiagnosed abnormal genital bleeding.
• Breast cancer or a history of breast cancer.
• Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer).
• An active or history of deep vein thrombosis (DVT) or pulmonary embolism (PE).
• An active or history of arterial thromboembolic disease (e.g., stroke, heart attack).
• Severe liver dysfunction or disease.
• Severe kidney disease.
• Known anaphylactic reaction, angioedema, or hypersensitivity to the components of Angeliq Micro.
• Known or suspected pregnancy or are breastfeeding.

How to Store and Dispose of Angeliq Micro?

The official label provides strict guidelines for storing and discarding Angeliq Micro to maintain product integrity and ensure safety.

Storage Requirement	Regulatory Statement
Temperature	Store below 30 C; avoid excessive heat.
Protection	Keep in a cool, dry place protected from sunlight and moisture.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Guidelines

Do not use the tablets past the expiry date (EXP) printed on the packaging. To discard unused or expired medication, it should not be flushed down a toilet or placed in household trash. Instead, return the tablets to a pharmacy or an authorized drug take-back program for proper disposal, in accordance with local environmental regulations.